FDA approves Stealth's rare disease drug after past rejection, delay

The FDA approved Stealth BioTherapeutics’ treatment for the rare disease Barth syndrome, closing the book on a long drug development saga. The regulators on Friday granted accelerated approval to elamipretide, which will be branded as ...